Clinical utility of biomarkers in myocardial injury.
PURPOSE OF REVIEW: This review will focus on recent developments in biomarkers of myocardial injury. We will discuss the clinical utility of cardiac-specific troponin in the post-operative setting and highlight some of the most promising new biomarkers under development. RECENT FINDINGS: Troponin I and T, measured in the post-operative setting, have been recently shown to have strong short- and long-term prognostic information in cardiac and vascular surgery patients. This ability of troponins to risk stratify post-operative patients occurs independent of clinical factors and other biomarkers. Additionally, brain natriuretic peptide has garnered significant interest as a biomarker of neurohormonal activation and appears to yield independent prognostic information from troponins. Recent studies have introduced two new biomarkers, soluble CD40 ligand and ischemia-modified albumin, which may aid in both diagnostic and prognostic decision making. SUMMARY: The current data strongly supports the use of troponin I and T in post-operative non-cardiac and cardiac surgical patients to assist in identifying those patients at high risk for short- and long-term complications. Several promising new biomarkers are currently under development but further studies are warranted to define their role in the post-operative setting.[1]References
- Clinical utility of biomarkers in myocardial injury. Chan, M.Y., Pronovost, P.J. Current opinion in anaesthesiology. (2004) [Pubmed]
Annotations and hyperlinks in this abstract are from individual authors of WikiGenes or automatically generated by the WikiGenes Data Mining Engine. The abstract is from MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.About WikiGenesOpen Access LicencePrivacy PolicyTerms of Useapsburg
